Merck To Spend Up To $2.3B In Ablynx Licensing Deal
Belgian biopharmaceutical company Ablynx NV has inked a licensing agreement with Merck & Co. Inc. worth up to €1.7 billion ($2.3 billion) to develop methods for the body to fight cancer...To view the full article, register now.
Already a subscriber? Click here to view full article